Research Library — Page 41 | Reta Compare
3563 research articles. Page 41 of 143.
Articles
- Pediatric Compounded Peptide Use: Where the Boundaries Are
- Clinical Monitoring of Patients on Compounded GLP-1s
- Reporting Adverse Events from Compounded Peptides
- The FDA MedWatch System and Compounded Drug Reports
- Compounded Peptides and Health Savings Accounts (HSA/FSA)
- Traveling With Compounded Peptide Prescriptions
- The Return of Tirzepatide Compounding: Will It Happen?
- What Happens If Your Telehealth Pharmacy Is Sued
- Pharmacy Ownership Disclosure in Compounded GLP-1 Telehealth
- How to Read a Compounded Peptide Label
- FDA Guidance Document on Compounded GLP-1 Drugs (2026 Update)
- FDA Removes Tirzepatide from Drug Shortage List (Recap)
- The FDA 503A Bulks List and Peptides
- The FDA 503B Bulks List and Its Role
- FDA Warning Letters on Compounded Tirzepatide in 2025 and 2026
- FDA Form 483 Observations and What They Mean
- Import Alerts Targeting Compounded GLP-1 API
- The FDA Drug Shortage List: How It Works
- The Role of CDER in Peptide Regulation
- FDA Enforcement Priorities for 2026
- FDA Commissioner Statements on Compounded Peptides
- The 2024 Outsourcing Facilities Association Lawsuit
- Congressional Oversight of FDA Compounded Drug Policy
- FDA Inspection Authority Over Compounding Pharmacies
- The FDA Advisory Committee on Compounding